PEER-REVIEW | ANTI-AGEING MEDICINE |
HRT
SAFER USE OF
PERSONALISATION THROUGH
Sly Nedic discusses the ongoing debate concerning the use of conventional HRT and bioidentical HRT, and why personalisation is paramount to increase the safety and efficacy of treatment
48 ❚ January/February 2013 |
prime-journal.com
ABSTRACT
Full title Safer use of HRT through personalisation: emphasising preventive genetic testing and nutrigenetics for the modulation of oestrogen metabolism
During menopause, the hormonal metabolism undergoes significant changes, leading to some typically unpleasant symptoms such as hot flushes and anxiety, and leading to an increase in the relative risk of cardiovascular disease, osteoporosis and declined cognition. In order to overcome these symptoms, hormone replacement therapy (HRT) is usually prescribed. As recent data has shown the association between HRT and the risk of breast cancer, the routine prescription of HRT has become a significant concern for both patients and physicians. Despite an ongoing debate between conventional HRT and bioidentical HRT (BHRT) users, the purpose of this article is to show that the risk of breast cancer is a result of patients’ individual oestrogen metabolism, and that personalisation is the key to increased safety when using HRT. Therefore, before prescribing any HRT, including BHRT, an assessment of the patient’s genetic make-up for the production of dangerous oestrogen metabolites, and an identification of her oestrogen load from endogenous oestrogens, environmental oestrogens, and dietary oestrogens should be undertaken. This will allow the physician to estimate the most adapted hormonal dosage, as well as evaluate whether the beneficial effect of HRT will outbalance the potential risk of developing breast cancer. Treatment with BHRT then becomes personalised and safe. In order to increase safety and — in addition to the adapted hormonal dosage — personalised nutritional modulation of oestrogen metabolism is prescribed knowing the specific single nucleotide polymorphism of the genes involved in oestrogen metabolism.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76